- $243.27bn
- $269.82bn
- $45.81bn
- 93
- 25
- 89
- 77
REG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Capivasertib Phase III trial met primary endpoints
AnnouncementREG - AstraZeneca PLC - Update on MESSINA Phase III trial
AnnouncementREG - AstraZeneca PLC - Imfinzi + Imjudo approved in advanced liver cancer
AnnouncementREG - Polar Cap Glb Health PCGH ZDP PLC - Top Ten Equity Holdings and Exposures
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Board Committee Changes
AnnouncementREG - AstraZeneca PLC - Koselugo approved in Japan for NF1
AnnouncementREG - AstraZeneca PLC - Tezspire approved in Japan for severe asthma
AnnouncementREG - AstraZeneca PLC - Ultomiris approved in EU for gMG
AnnouncementREG - AstraZeneca PLC - Lynparza approved in China for ovarian cancer
AnnouncementREG - AstraZeneca PLC - Tezspire approved in the EU for severe asthma
AnnouncementREG - AstraZeneca PLC - Evusheld approved in EU for COVID-19 treatment
AnnouncementREG - JPMorgan Inv. Trusts - Ten Largest Investments
AnnouncementREG - AstraZeneca PLC - Evusheld positive CHMP opinion in EU
AnnouncementREG - AstraZeneca PLC - Danicopan Phase III trial met primary endpoint
AnnouncementREG - AstraZeneca PLC - Nirsevimab recommended for approval in EU by CHMP
AnnouncementREG - AstraZeneca PLC - Forxiga approved in China for CKD
AnnouncementREG - AstraZeneca PLC - Imfinzi approved in US for biliary tract cancer
Announcement